Left-ventricular dysfunction, heart vagus influences and angiotensin II effects after doxorubicin perfusion in isolated rat hearts

Wicher C, Biewald G-A
**Left-ventricular dysfunction, heart vagus influences and angiotensin II effects after doxorubicin perfusion in isolated rat hearts**

C. Wicher, G.-A. Biewald

Chronic treatment with doxorubicin (DXR) or other anthracyclines causes impairments in myocardial function and, eventually, results in dilative cardiomyopathy (DCM). It is also associated with changes in the action of the renin-angiotensin II (AII) system and AII receptor density. Aim of the present study was to investigate effects of DXR perfusion (up to 60 min) of isolated, vagally innervated rat hearts on vago effects regarding cardiac activity and possible changes by DXR in the modulation of vago effects by angiotensin II (AII), for comparison with known chronic anthracycline effects. Electrical (surface ECG) and mechanical (left-ventricular pressure, LVP) cardiac activity were recorded. Vago stimulation (10 Hz, 10 V) caused prolonged ECG intervals, reduced heart rate (HR) and negative inotropic effects (reduced left-ventricular systolic pressure P<sub>S</sub>, decelerated contraction). Perfusion with DXR-containing Tyrode (10–40 µmol/L DXR) caused dose-dependent and progressive functional impairments, similar to those known from long-term anthracycline treatment in humans: prolonged ECG intervals, decreased HR, reduced P<sub>S</sub> and a prolonged contraction period. The effects of heart vagus stimulation on ECG and LVP were reduced during DXR perfusion.

However, DXR perfusion did not affect the positive chronotropic and inotropic effects of AII (1 µmol/L, applied subsequently to DXR) as well as the modulatory function of AII on cardiac vago actions: AII blocking effects were comparable to control. These results are at some variance with clinical findings in long-term anthracycline treatment. It is concluded that short-time DXR administration was not enough for establishing changes in the AII system observed during long-term treatment. *J Clin Basic Cardiol* 1999; 2: 259–66.

**Keywords:** doxorubicin, myocardial function, ECG, vagus stimulation, angiotensin II
shift of the sympathetic-vagal balance towards the sympathetic side. On the other hand, a generally reduced autonomic nervous activity is reported for DCM patients that could contribute to the observed cardiac desensitization [25].

This study investigates time- and concentration-dependent effects of short-time DXR perfusion on electrical (surface ECG) and mechanical (left-ventricular pressure) cardiac activity as well as on its modification by vagus stimulation and angiotensin II in isolated rat hearts (modified Langendorff preparation). Observed alterations in cardiac activity during DXR perfusion are discussed and compared with those observed during the pathogenesis of the DCM (chronic anthracycline treatment).

### Materials and Methods

The experiments were performed on adult female HanWistar rats (200–250 g body weight, Institute for Pharmacology and Toxicology, Friedrich Schiller University Jena). The rats were anaesthetized by combinatory injection containing ketamine and rompune: 1 mg ketamine hydrochloride/kg body weight (Mallinckrodt Vet, Burgwedel, Germany) and 0.2 mg rompune/kg body weight (rompune = 2-(2,6-Xylidino)-5,6-dihydro-4 H-1,3-thiazine-hydrochloride, Bayer Leverkusen, Germany), whereby about 50 per cent of the bolus was i.m. injected into each hindlimb of awake rats. About 5 minutes after injection, the right N. vagus was cut in the mid-neck region, and the distal trunk was carefully dissected free using fine forceps. The vagus was kept moist using isotonic saline solution. Surgery had a duration of 10 minutes in maximum. The rats were killed by cervical dislocation. The heart with intact right vagus trunk was quickly removed and immersed in cold (4 °C) Tyrode solution (in mmol/L: 150 NaCl, 5.4 KCl, 2.5 CaCl₂, 0.5 MgSO₄, 11.1 glucose, 5 HEPES, pH = 7.4). The aorta was cannulated and the heart was mounted in a perfusion apparatus (Langendorff preparation). The heart was retrogradely perfused through the aorta at a constant perfusion pressure of 40 cm H₂O. After washing the heart by perfusion with oxygenated Tyrode (37 °C) for 10 min, the heart was perfused by recirculating Tyrode solution. The hearts were allowed to beat spontaneously.

After a 30 min stabilization period, the distal end of the right cardiac N. vagus was positioned on a platinum electrode which was connected with an electrical stimulator (Technical and Scientific Equipment, Bad Homburg, Germany). In each stimulation period, a 10 s impulse train of square pulses (5 ms single pulse duration, stimulation voltage: 10 V, stimulation frequency: 10 Hz) was applied on vagus nerve (control recording contains 3 such stimulation periods, with temporal distances each of 1 minute at least). In our experiments, we stimulated only the right vagus trunk, because it is known that the cardiac innervation of the right vagus is generally stronger than that of the left one [26, 27]. Right vagus stimulation effects on cardiac actions were indeed stronger than effects by left vagus stimulation [19]. The vagus nerve was stimulated by a constant frequency of 10 Hz which corresponds to physiological conditions of N. vagus [28].

### Experimental protocol

In 15 experiments, 30 min after preparation of the heart, a control recording of LVP and ECG (see above) were performed. Then doxorubicin (DXR, CALBIOCHEM NOVA-BIOCHEM, La Jolla, USA, tested dose range 10–40 µmol/L, one dose per experiment, 5 rats per DXR dose) was administered to the Tyrode solution. Recording was repeated up to the individual end of spontaneous heart beating period, once per 5 min. In dependence on applied DXR dose the isolated hearts beat after DXR application for up to 60 min (10 µmol/L DXR) and 35 min (40 µmol/L DXR), respectively.

In another 15 experiments, 30 min after the end of heart preparation, 3 control vagus stimulations (right N. vagus, stimulation parameters as described above) were performed (once per minute). Subsequently DXR was added (10–40 µmol/L, one dose per rat). After a 4 min stimulation period, vagus stimulations were repeated every 5 min up to the individual end of spontaneous beating of the heart.

In 5 separate experiments, after control stimulation, 10 µmol/L dantrolene (dantrolene sodium, Research Biochemicals International, Natric, USA, an inhibitor of the intracellular ryanodine receptor which causes a blockade of calcium-induced calcium release from sarcoplasmatic reticulum [29, 30]), and 5 minutes later 20 µmol/L DXR were added to the perfusion solution. Vagus stimulations were repeated every 10 min starting after addition of the drugs up to the individual end of spontaneous beating of the heart.

In 5 separate experiments, 20 min after addition of 20 µmol/L DXR, 1 µmol/L angiotensin II (AII, BACHEM Heidelberg, Germany) was administered to perfusion solution. After 4 min perfusion, next vagus stimulation was performed, stimulations were repeated all 5 min up to the individual end of spontaneous heart beating.

### Parameters and data analysis

The time course of left-ventricular pressure (LVP) was recorded via pressure transducer (pressure evaluation unit, FMI, Seecheim, Germany), amplified (amplifier, FMI, Seecheim, Germany) and recorded by TIDA software (HEKA Elektronik, Lambrecht, Germany). Systolic pressure (Ps) was calculated from LVP. Time courses of contraction and relaxation periods of LVP were described by single exponential functions (time constants: τc for contraction, and τr for relaxation). ECG was recorded directly from the cardiac surface via surface electrodes which were positioned near the heart base and the apex. From ECG recording, the PQ, QRS, ST and QT intervals were measured similarly as described in [34]. In our analysis, the isoelectric point was determined by taking the average of 9 voltage values directly before the Q wave. The Q wave was taken as the point where the isoelectric line intercepts an interpolation of the upstroke of the R wave. The S wave was taken as a clear minimum after the R wave. The apex of the T wave (aT) was taken as the clear maximal point after the S wave. The QR5 (from the apex of the Q wave to the apex of the S wave) and ST5 (from the apex of the S wave to the apex of the T wave) intervals were calculated from these data. The P, Q, R, S and T wave voltages (mV) were measured by determining of the averaged signal from the isoelectric baseline. The heart rate was calculated from R-R interval. All measurements were made on tracings of 10 consecutive cardiac cycles.

Direct doxorubicin-induced changes in the electrocardiographic intervals were determined from individual rats as changes from the pretreatment values. Vagus stimulation effects (taken from the end of each stimulation period) as well as angiotensin II-induced modulation of vagus stimulation effects were determined as changes from prestimulation values (control values) and from vagus stimulation-induced values before angiotensin II addition, respectively.
Pre- and posttreatment figures were compared to each other by ANOVA (for one factor, combined with Dunnet’s post test, PRISM, GraphPad Software, San Diego, USA). All data are means ± standard errors of the mean (SEM) of independent experiments.

**Results**

**Control recording of LVP and ECG and vagus stimulation**

In isolated hearts, a spontaneous heart rate of 184 ± 47/min was recorded (Table 1). The systolic pressure $P_S$ amounted to 67.5 ± 24.2 mmHg. Fitting single exponential functions to the time courses of contraction and relaxation revealed a time constant of contraction $\tau_C$ of 11.9 ± 5.1 ms and a time constant of relaxation $\tau_R$ of 31.4 ± 6.8 ms. The time parameters of the ECG were: PQ time: 51.7 ± 5.0 ms, QRS time: 11.9 ± 3.6 ms, ST time: 15.6 ± 3.2 ms (QT interval: 27.5 ± 3.4 ms). As a characteristic ECG amplitude the R-S amplitude was recorded after 10-fold magnification: 3.18 ± 0.79 V. Because of the strong dependency of ECG amplitudes on the momentary position of ECG electrodes on the cardiac surface, the other ECG peak amplitudes had great deviations and were therefore not considered. For comparison control figures of ECG and LVP parameters recorded on isolated, vagally innervated rat hearts and in anesthetized rats [33] are given in Table 1.

Stimulation of the right vagus (square pulse trains, 10 Hz, 10 V, 10 s stimulation period) caused reductions in heart rate by about 52 ± 14 % and in left-ventricular pressure amplitude ($P_0$) by about 48 ± 18 %. The time constant of contraction ($\tau_C$) was prolonged by about 34 ± 11 %. In the ECG, there were significant prolongations of the ST time interval (83 ± 18 %) during vagus stimulation, but only slight prolongations in the PQ and QRS intervals (by about 5 % each, ECG changes not shown). Vagus stimulation effects during Tyrode perfusion were set to 100 % in each experiment.

**AII modulation (under physiological conditions)**

In Figure 1 original registrations of LVP in isolated heart and effects of vagus stimulation on LVP before and after addition of 2 $\mu$mol/L AII to Tyrode (without DXR) are shown (physiological AII effect).

In this experiment, AII caused an increase in heart rate by about 32 % (from 217/min to 287/min, positive chronotropic effect of AII), an increase in the left-ventricular systolic pressure (from 66 to 84 mm Hg, increase of 40 %) and a decrease in $\tau_C$ (from 13.7 to 8.6 ms, decrease by about 37 %, positive inotropic effects of AII). The ST time interval of ECG was reduced by about 20 % (not shown).

AII also caused a nearly complete inhibition of vagus stimulation effects (Figure 1): vagus stimulation after AII addition caused only a slight reduction in heart rate and a slight increase in $\tau_C$ (by about 5 % each), and it had nearly no effects on systolic pressure (Figure 1) and on ST interval of ECG (ECG effects not shown).

**DXR effects on ECG and LVP**

Depending on the DXR concentration in the Tyrode solution, the isolated hearts were still beating spontaneously for up to 60 min after addition of 10 $\mu$mol/L and for up to 35 min after addition of 40 $\mu$mol/L DXR. Within this time, progressive impairments of ventricular function were observed, such as reductions in HR, prolonged ECG times (QRS time and ST time), decreased systolic pressure $P_S$ and increased $\tau_C$. Nevertheless, $\tau_R$ remained nearly unchanged during DXR perfusion. An example of single cycles of original two-cham-
nel recordings of ECG and LVP from isolated rat heart before and 30 min after addition of 20 µmol/L DXR to Tyrode is given in Figure 2. Reduced left-ventricular pressure amplitude and slower increase in pressure during contraction phase are evident.

These changes were stronger after addition of 40 µmol/L DXR. The dose-dependence of changes in HR, SαT and τC are shown in Figure 3. In this figure changes in SαT and τC are given without a correction for frequency-dependent changes. Values of all parameters recorded in control stimulation (Tyrode perfusion) were set to 100 %. Significant changes (P < 0.05) in the above parameters occurred after perfusion times of 10 min or more with at least 20 µmol/L DXR in Tyrode. As an example, after 30 min perfusion with 20 µmol/L DXR the heart rate was reduced to 63 ± 9 % of control, the SαT interval of ECG was increased by 81 ± 30 % of control and the time constant τC was increased by 65 ± 20 % of control.

DXR effects on vagus stimulation and AII modulation

An example of original time course of left-ventricular pressure (left column: without vagus stimulation) as well as of effects of vagus stimulation on left-ventricular pressure (right column: vagus stimulation effect) in isolated rat heart (modified Langendorff preparation) is given in Figure 4.

During DXR perfusion, PS and HR as well as the effects of vagus stimulation on ECG and LVP parameters were strongly decreased (for example see the second line of curves in Figure 4, LVP was recorded after 24 min perfusion with 20 µmol/L DXR-containing Tyrode: “24 min DXR”).

AII was administered 25 min after heart perfusion with DXR-containing Tyrode. Also in this perfusion solution, AII had positive chronotropic and inotropic effects (third line of figures: “31 min DXR, 5 min AII”, left part) and the effects of vagus stimulation on heart rate and LVP were further reduced after addition of 1 µmol/L AII to the DXR-containing perfusion solution (third line of figures, right part). Therefore, modulatory action of AII regarding vagus stimulation effects was not affected by DXR in isolated rat heart. At the end of experiment (last line in Figure 4), the heart beat irregularly and feebly, and the vagus stimulation effects had disappeared.

Figure 2. Superimposed single time courses of left-ventricular pressure (LVP, dashed line) and electrocardiogram (ECG, solid line), recorded in isolated rat hearts before (above) and 30 min after addition of 20 µmol/L doxorubicin (DXR, below) to Tyrode solution. P wave was chosen as common origin of the curves. Note that DXR induces a slowing in contraction phase and increases in ECG intervals (PQ and SαT).

Figure 3. Normalized changes in heart rate (HR, A), SαT (B) and time constant of left-ventricular contraction τC (C) during perfusion of isolated heart with doxorubicin (DXR, 10–40 µmol/L)-containing Tyrode (parameters before DXR addition were set to 1). 10 µmol/L DXR: solid line and open squares, 20 µmol/L DXR: dash-dotted line and filled circles, 40 µmol/L DXR: dashed line and open rhombus. Means and SD of 5 experiments. Note that DXR perfusion caused reductions in heart rate by up to 50 %, and increases in SαT by up to 150 %, and increase in τC by up to 75 % (after 25 minutes perfusion with 40 µmol/L DXR-containing Tyrode).
The time dependence of DXR perfusion on vagus stimulation effects on HR, SαT and τC are shown in Figure 5: Higher DXR concentrations as well as longer perfusion duration caused smaller vagus stimulation effects. As an example, after 30 min perfusion with 20 µmol/L DXR in Tyrode (see “end of experiment” in Figure 5), chronotropic vagus effect was reduced to 58 ± 20 %, vagus stimulation effect on SαT was reduced to 45 ± 8 %, vagus stimulation effect on τC was reduced to about 44 ± 14 % of each control vagus stimulation effect.

In Figure 6 the time courses of the parameters HR, SαT, P5 and τC during one characteristical DXR-experiment are given. Vertical arrows give the effects of vagus stimulation at several time points of the experiment. We found reductions in HR and P5 (by about 37 % and 55 %, respectively) and increases in SαT and τC (by about 39 % and 29 %, respectively) during DXR perfusion (direct DXR effects). Furthermore, vagus stimulation effects on all parameters were progressively reduced (by up to 70 % regarding HR; by up to 57 % regarding SαT; by up to 70 % regarding P5 and by up to 54 % regarding τC) during 20 minutes of DXR perfusion. After addition of AII (1 µmol/L), significant improvements (though only for a few minutes) were obtained including an increase in HR and P5, and shortenings in SαT and τC (positive chronotropic and inotropic effects).
All effects). Consequently, after a period of 5 to 10 minutes, all parameters, except $P_S$, approached baseline levels (recorded before DXR application). Also the modulatory effect of AII regarding vagus stimulation effects was preserved during DXR perfusion: Vagus stimulation caused progressively smaller effects, especially on HR and $P_S$. At the end of the experiment, AII had nearly completely suppressed the vagus effects regarding cardiac action (Figure 6).

**Dantrolene and caffeine modulate the DXR effects on cardiac action and vagus stimulation**

The effects of dantrolene and caffeine regarding DXR-induced changes in heart rate and chronotropic vagus stimulation effect are shown in Figure 7. Dantrolene (10 µmol/L) increased the DXR effect regarding its influence on heart rate (Figure 7A) and cardiac contractility ($\tau_C$, Figure 7C). After a 40 min perfusion period with dantrolene and DXR (20 µmol/L), heart rate was significantly ($P < 0.05$) more strongly reduced (by about 15%) than after perfusion with DXR-containing Tyrode solution. The DXR effects on systolic pressure and time constant of contraction ($\tau_C$) were also increased after perfusion with dantrolene and DXR (both by about 15%). Additionally, reductions in heart rate and in cardiac contractility caused by vagus stimulation (right $N$. vagus, 10 Hz, 10 V) were smaller after perfusion with dantrolene and DXR, compared with stimulation effects after perfusion with DXR-containing Tyrode.

In contrast to this, caffeine (10 mmol/L) reduced the DXR-induced effects: after a 40 min perfusion period with caffeine and DXR (20 µmol/L), the decreases in HR (Figure 7B) and $P_S$ (not shown) were significantly ($P < 0.05$) smaller (by about 15%) than after perfusion with DXR-containing Tyrode solution. Vagus stimulation effects after perfusion with caffeine and DXR were stronger than those after DXR application alone.

**Discussion**

The aim of this study was to investigate changes in cardiac vagus function and its modulation by AII during short-time perfusion of DXR in isolated hearts. There was a good parallelity between ECG parameters recorded in the isolated rat heart and previously reported values for anesthetized [33] or conscious DXR-treated rats [34]. Heart rate *in vitro* was significantly lower than in anesthetized rats or even conscious animals where the heart rate is regulated by the vegetative innervation (*in vivo*).

The DXR dose in clinical anticancer therapy amounted to maximal 550 mg per square meter of body-surface area [1]. This clinically applied dose approximately corresponds to about 20 µmol/L (estimated for an adult man with about 1.5 square meters of body-surface area and about 80 kg body weight). Therefore, DXR concentrations in our experiments (10–40 µmol/L) were in a comparable range as reported from clinical studies [1], but were also comparable with *in vivo* experiments on rats (4 mg DXR/kg body weight, applied up to 5 times per week [34]), experiments on calcium release channels from cardiac sarcoplasmatic reticulum of dog cardiac muscles (2.5–10 µmol/L, [9]) and experiments on isolated sarcoplas-}

...
effects on heart action and vagus effects. These observations could be a sign that intracellular ryanodine receptors seem to be involved in mediation of DXR effects regarding the reduction of intracellular calcium concentration [8].

In contrast, the angiotensin II (AII)-induced modulation of vagus effects were not affected by DXR perfusion. After addition of 1 µmol/L AII subsequently to DXR, we observed clear effects of AII on heart rate and cardiac contractility (positive chronotropic and inotropic effects). Also the modulatory role of AII regarding vagus control in the DXR-perfused heart was comparable with AII modulation effects under control conditions. These findings could base on the different intracellular mechanisms underlying DXR effects on the one hand and AII effects on the other hand which do not seem to interact: AII binds on myocardial AT1 receptors and increases the intracellular calcium level via calcium release from intracellular stores (activation of IP3 receptors) as well as via phosphorylation of L-type Ca2+-channels (PKC activation) and calcium inward current [15–17, 35]. DXR mediates its action via intracellular myocardial ryanodine receptors (at least partially) which were initially activated and subsequently irreversibly inhibited by DXR [9]. Thus, it should not be surprising that the modulatory role of AII was preserved also during short-time DXR perfusion, and was comparable with AII effects under physiological conditions [19].

Clinical data indicate that chronic anthracycline treatment causes functional changes in the renin-angiotensin system: the available concentration of angiotensin II or its precursors in the plasma as well as the activation of α- and β-adrenergic receptors in the peripheral effector organs was markedly reduced [22]. Concluding from our results, the short DXR-contamination period applied in our experiments (maximal 60 min perfusion) seemed not to be sufficient to cause comparable changes in the AII system in vivo.

Acknowledgements

This study was supported by a Grant of the Federal Department of Education and Research of the F.R.G. (Project Number: 01ZZ9602).

We are grateful to Prof. Dr. K. Schrör (Institute of Pharmacology, Heinrich Heine University Düsseldorf) for constructive criticism of the manuscript.

References


Mitteilungen aus der Redaktion

Besuchen Sie unsere
zeitschriftenübergreifende Datenbank

☑ Bilddatenbank  ☑ Artikeldatenbank  ☑ Fallberichte

e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meist en der markt-
üblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑ Bestellung e-Journal-Abo

Haftungsausschluss

Die in unseren Webseiten publizierten Informationen richten sich ausschließlich an geprüfte
und autorisierte medizinische Berufsgruppen und entbinden nicht von der ärztlichen Sorg-
faltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen
und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den
Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Do-
sierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren,
noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsan-
sprüche.

Bitte beachten Sie auch diese Seiten:

Impressum  Disclaimers & Copyright  Datenschutzerklärung